88620 Federal Register / Vol. 88, No. 245 / Friday, December 22, 2023 / Notices 

the key elements of a safety station 

program so that facility-specific detailed 

plans and programs can be developed in 

an informed manner. Safety station 

programs are voluntary and are not 

mandatory for Federal facilities. The 

costs and expenses to establish and 

operate a safety station program are the 

responsibility of the occupant agency or 

agencies sponsoring the program and 

not GSA or HHS, except to the extent 

GSA or HHS, or both, are sponsoring a 

program in a facility where they are 

occupant agencies. 

The importance of keeping opioid 

reversal agents easily accessible has 

been highlighted by the U.S. Surgeon 

General and the Centers for Disease 

Control and Prevention (CDC). On April 

5, 2018, Surgeon General Jerome Adams 

issued an advisory recommending that 

more individuals keep naloxone on 

hand. The link to the advisory can be 

found at https://www.hhs.gov/ 

surgeongeneral/reports-andpublications/addiction-and-substancemisuse/advisory-on-naloxone/ 

index.html. On October 5, 2018, the 

CDC’s National Institute for 

Occupational Safety and Health 

(NIOSH) issued the fact sheet ‘‘Using 

Naloxone to Reverse Opioid Overdose 

in the Workplace: Information for 

Employers and Workers’’ to assist 

workplace decision makers in 

establishing a naloxone availability and 

use program. The link to the white 

paper can be found at https://

www.cdc.gov/niosh/docs/2019-101/ 

pdfs/2019-101.pdf. The Surgeon General 

advisory and the CDC NIOSH fact sheet 

highlight the importance of having 

opioid reversal agents in public spaces 

for quick access and why they should be 

included in an agency’s safety station 

program. 

Krystal J. Brumfield, 

Associate Administrator, Office of 

Government-wide Policy, U.S. General 

Services Administration. 

Rachel L. Levine, 

Assistant Secretary for Health, U.S. 

Department of Health and Human Services. 

[FR Doc. 2023–28207 Filed 12–21–23; 8:45 am] 

BILLING CODE 6820–14–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–24–1074; Docket No. CDC–2023– 

0100] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a continuing information collection, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled Colorectal 

Cancer Control Program (CRCCP) 

Monitoring Activities. CDC is requesting 

an Extension to OMB Control No. 0920– 

1074 to continue information collection 

via an annual survey, a clinic-level data 

collection instrument, and a quarterly 

recipient-level program update survey. 

DATES: CDC must receive written 

comments on or before February 20, 

2024. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2023– 

0100 by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to 

the address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; 

Telephone: 404–639–7118; Email: omb@

cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Colorectal Cancer Control Program 

(CRCCP) Monitoring Activities (OMB 

Control No. 0920–1074, Exp. 03/31/ 

2024)—Extension—National Center for 

Chronic Disease Prevention and Health 

Promotion (NCCDPHP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

Colorectal cancer (CRC) is the second 

leading cause of death from cancer in 

the United States among cancers that 

affect both men and women. There is 

substantial evidence that CRC screening 

reduces the incidence of, and death 

from the disease. Screening for CRC can 

detect disease early when treatment is 

more effective, and can prevent cancer 

by finding and removing precancerous 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 245 / Friday, December 22, 2023 / Notices 88621 

polyps. Of individuals diagnosed with 

early stage CRC, more than 90% live 

five or more years. Despite strong 

evidence supporting screening, only 

68.8% of adults currently report being 

up-to-date with CRC screening as 

recommended by the U.S. Preventive 

Services Task Force in 2018, with more 

than 22 million age-eligible adults 

estimated to be untested. To reduce CRC 

morbidity, mortality, and associated 

costs, use of CRC screening tests must 

be increased among age-eligible adults 

with the lowest CRC screening rates. 

The purpose of the Colorectal Cancer 

Control Program (CRCCP) is to partner 

with health systems and their 

individual primary care clinics to 

implement Evidence-based 

interventions (EBIs) to increase CRC 

screening among defined populations of 

adults ages 50–75 that have CRC 

screening rates lower than the national, 

regional, or local rate. In 2020, CDC 

issued the funding opportunity, Public 

Health and Health System Partnerships 

to Increase Colorectal Cancer Screening 

in Clinical Settings (DP20–2002), a 5- 

year cooperative agreement to increase 

CRC screening among defined 

populations of adults ages 50–75 that 

have CRC screening rates lower than the 

national, regional, or local rate. DP20– 

2002 funds recipients to partner with 

health systems and their primary care 

clinics to implement multiple EBIs, 

partner with organizations to support 

implementation of EBIs in those clinics, 

and collect high-quality clinic-level data 

when a clinic is recruited to participate 

(baseline) and annually thereafter to 

monitor EBI implementation and assess 

screening rate changes. DP20–2002 also 

requires recipients to conduct a formal 

capacity/readiness assessment of 

potential clinics to implement EBIs, use 

assessment findings to select 

appropriate EBIs for implementation, 

and provide clinics with limited 

financial resources to support follow-up 

colonoscopies for under- and uninsured 

patients after an abnormal CRC 

screening test. 

CDC proposes three information 

collections—the Annual Awardee 

Survey, the Clinic-Level Data Collection 

Instrument, and the Quarterly Program 

Update—to reflect the strategies and 

objectives detailed in DP20–2002. CDC 

will conduct data collections for each of 

these three proposed activities among 

all 35 recipients following the end of 

each program year which runs from July 

1–June 30. 

The Annual Awardee Survey assesses: 

(1) program management; (2) clinic 

readiness assessment activities; (3) data 

management; (4) technical assistance 

(TA) needs; (5) partnerships; and (6) the 

effect of COVID–19 on CRC 

implementation at the recipient level. 

The Clinic-level Information 

Collection Instrument assesses: (1) 

health system and clinic characteristics; 

(2) program reach; (3) CRC screening 

practices and outcomes; (4) clinics’ 

quality improvement and monitoring 

activities; (5) EBI implementation; and 

(6) additional factors that affect EBI 

implementation over time. 

The Quarterly Program Update will 

collect standardized recipient-level 

information on aspects of program 

management, including: (1) quarterly 

program expenditures; (2) current staff 

vacancies; (3) program successes and 

challenges; (4) current TA needs; and (5) 

the effect of COVID–19 on CRCCP 

implementation at the recipient level. 

These data are collected quarterly to 

enable rapid reporting of programmatic 

information to support CDC program 

consultants in providing tailored and 

meaningful TA. 

This information collection enables 

CDC to gauge progress in meeting 

CRCCP program goals and monitor 

implementation activities, evaluate 

outcomes, and identify recipients’ TA 

needs. In addition, data collected will 

inform program improvement and help 

identify successful activities that need 

to be maintained, replicated, or 

expanded. CDC is requesting a 3-year 

Extension to the Colorectal Cancer 

Control Program (CRCCP) Monitoring 

Activities collection (OMB No. 0920– 

1074). The total estimated annualized 

burden is 760 hours. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hr) 

Total 

burden 

(in hr) 

CRCCP Recipients ....... CRCCP Annual Awardee Survey ......................................... 35 1 15/60 9 

CRCCP Clinic-level Information Collection Instrument ........ 35 24 50/60 700 

CRCCP Quarterly Program Update ..................................... 35 4 22/60 51 

Total ....................... ............................................................................................... .................... ........................ .................... 760 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2023–28174 Filed 12–21–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifier: CMS–8003] 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 

(PRA), Federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension or reinstatement of an existing 

collection of information, and to allow 

a second opportunity for public 

comment on the notice. Interested 

persons are invited to send comments 

regarding the burden estimate or any 

other aspect of this collection of 

information, including the necessity and 

utility of the proposed information 

collection for the proper performance of 


ddrumheller on DSK120RN23PROD with NOTICES1